Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

If you had a reputation for being a know-it-all as a kid, you’re likely now the person with a trusted list of trivia questions and answers on file. Not only that, but you probably love sentences that ...

1. Would you rather be able to fly or be able to breathe underwater? 2. Would you rather your crush be able to read your mind or have access to your internet history? 3. Would you rather swim in the ...

The festive season is here, so you know what that means: it's party time! We've got just what you need to start up the conversation and get everyone in the mood. Whether you're playing Never Have I ...

Cardiovascular disease is a term used to describe diseases of the heart and blood vessels. Some of the common types of cardiovascular disease include coronary artery disease, heart attack, and heart ...